Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 12;19(6):803-806.
doi: 10.2215/CJN.0000000000000433. Epub 2024 Jan 12.

Hemoadsorption

Rinaldo Bellomo  1   2   3   4 , Ravindra L Mehta  5 , Lui G Forni  6   7 , Alexander Zarbock  8 , Marlies Ostermann  9 , Claudio Ronco  10   11   12 ; Acute Disease Quality Initiative Hemoadsorption Working Group
Collaborators, Affiliations

Hemoadsorption

Rinaldo Bellomo et al. Clin J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

R. Bellomo reports Consultancy: Consulting fees from Baxter and Jafron Biomedical; Research Funding: Grant support from Baxter and Jafron Biomedical; Honoraria: Baxter and Jafron Biomedical; and Advisory or Leadership Role: Advisor to Baxter and Jafron Biomedical. L.G. Forni has Ownership Interest in Spiden AG; Consultancy: Exthea Medical and Zafron Biomedical Company; Research Funding: Baxter; Honoraria: Astute Medical, Baxter, Biomerieux, Exthera Medical, Fresenius, and Paion; Advisory or Leadership Role: ESICM General Secretary (European Society of Intensive Care Medicine: Unpaid) and FICM (Faculty of Intensive Care Medicine: Unpaid); and Speakers Bureau: Baxter. R.L. Mehta reports Consultancy: Abiomed, Abbott, Alexion, AM-Pharma, Baxter, bioMerieux, Fresenius, GE Healthcare, Guard, Intercept, Mallinckrodt, Novartis, Renasym, Renibus, Sanfi, SeaStar, Sphingotec, and Unicycive; Ownership Interest: CRRT Inc. and DAECOS; Research Funding: Fresenius and Fresenius-Kabi; and Honoraria: Baxter, CHF Solutions, Medtronic, and Nova Biomedical. M. Ostermann reports Research Funding: Baxter, Biomerieux, Fresenius Medical Care, and La Jolla Pharma; and Advisory or Leadership Role: Editorial Board of Annals of Intensive Care, Blood Purification, Intensive Care Medicine, Journal of Critical Care, and Nephrology Dialysis Transplantation; Member of Executive Committee of European Society of Intensive Care Medicine; and Member of Executive Committee of Intensive Care Society United Kingdom. C. Ronco reports Consultancy: Aferetica, Asahi, Astrazeneca, Baxter, B.Braun, Biomerieux, Bioporto, Cytosorbents, Estor, FMC, GE Healthcare, Jafron Biomedical, Medica, Medtronic, Nipro, Ortho, and Toray; Ownership Interest: CR19 and New Progress Service srl; Honoraria: Aferetica, Astute, Baxter, B.Braun, Estor, Fresenius, GE, Jafron, Medtronic, and Toray; Advisory or Leadership Role: Associate editor of Nephrology Dialysis and Transplantation and Editor in chief of Blood Purification and Contributions to Nephrology and Cardiorenal Medicine; and Speakers Bureau: Asahi, Baxter, Biomerieux, Estor, GE, Jafron, and Nipro. A. Zarbock reports Consultancy: Alexion, AM Pharma, Anomed, Astellas, BioMerieux, Baxter, Bayer, Fresenius, Guard Therapeutics, La Jolla Pharmaceuticals, Novartis, and Paion; Research Funding: Baxter, BioMerieux, Deutsche Forschungsgemeinschaft, Else-Kröner Fresenius Stiftung, and Fresenius; Honoraria: Lecture fees from: Baxter, BioMerieux, Fresenius, and Paion; and Advisory or Leadership Role: Astronomy & Astrophysics, Guard Therapeutics, Journal of Immunology, Piaon, and Springer journal (Anästhesist).

Figures

Figure 1
Figure 1
Schematic representation of various extracorporeal techniques that use isolated or combined HA mechanisms and principles. The first panel shows isolated direct HA. The second panel shows the combination of plasmafiltration, plasma adsorption, and reinfusion. The third panel shows the combination of plasmafiltration with plasma adsorption and reinfusion with additional in series CKRT or hemodialysis. The fourth panel shows plasmafiltration with double adsorption using sorbents with different specificity for different solutes. The fifth panel shows direct HA followed by CKRT or hemodialysis in series. CKRT, continuous KRT; HA, hemoadsorption; DPMAS, double plasma molecular adsorption system.
See this image and copyright information in PMC

References

    1. Ronco C, Bellomo R. History and development of sorbents and requirements for sorbent materials. Contrib Nephrol. 2023;200:2–7. doi:10.1159/000529569 - DOI - PubMed
    1. Ferrari F, Manera M, D’Auria L, De Rosa S, Ronco C. Hemoperfusion in poisoning and drug overdose. Contrib Nephrol. 2023;200:218–241. doi:10.1159/000526730 - DOI - PubMed
    1. Ricci Z, Romagnoli S, Reis T, Bellomo R, Ronco C. Hemoperfusion in the intensive care unit. Intensive Care Med. 2022;48(10):1397–1408. doi:10.1007/s00134-022-06810-1 - DOI - PMC - PubMed
    1. Shum HP, Leung YW, Lam SM, Chan KC, Yan WW. Alteco endotoxin hemoadsorption in Gram-negative septic shock patients. Indian J Crit Care Med. 2014;18(12):783–788. doi:10.4103/0972-5229.146305 - DOI - PMC - PubMed
    1. Garbero E Livigni S Ferrari F, et al. . High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med. 2021;47(11):1303–1311. doi:10.1007/s00134-021-06501-3 - DOI - PubMed

Associated data